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Abstract
Background: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is
no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF
inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal
melanoma, lacks these mutations, however, their presence has been reported for CMM.
Case presentation: We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a
BRAFV600E mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a
week and she experienced a progression free survival of four months.
Conclusions: To our knowledge, this is the first described case of response to vemurafenib treatment in a patient
with ocular melanoma.
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Background
Two subtypes of primary ocular melanoma have been
described, uveal and conjunctival. Conjunctival malig-
nant melanoma (CMM) is a rare condition with an inci-
dence of 0.2 to 0.8 per million in Caucasian populations.
It is a frequently lethal non-cutaneous neoplasm with an
average 10-year mortality rate of 30 % [1]. Studies over
the past two decades have revealed different genetic sub-
sets of melanoma [2–4]. Half of cutaneous melanomas
harbor activating mutations in BRAF and the most abun-
dant is BRAFV600E followed by BRAFV600K. However, the
most common form of ocular melanoma, uveal melan-
oma, lacks these mutations except from its smallest sub-
group, iris melanoma. CMMs have not been well
characterized at the genetic level, however, BRAFV600E
mutations have been reported in 14 % to 50 % [5–7].
At present no effective treatment is available for meta-
static CMM, hence the need for new therapies is essen-
tial. In contrast, treatment with the BRAF inhibitors
vemurafenib and dabrafenib is established for patients
with BRAFV600E and BRAFV600K mutated disseminated
cutaneous melanomas [8, 9]. BRAF status might also be
a predictive marker in deciding whether to use BRAF in-
hibitors for the treatment of patients with advanced
CMM [10]. Here we present a case of a patient with
metastatic CMM positive for the BRAFV600E mutation
who was treated with vemurafenib. To our knowledge,
there is no previously described treatment response to
vemurafenib in ocular melanoma.
Case presentation
The patient, a 53-year old Caucasian woman, initially
noticed a lesion in her right eye. After a medical ap-
pointment at the ophthalmologic clinic at a regional
hospital, a decision to remove the lesion was taken and
an operation was carried out in August 2011. The
pathology report showed a 13×11×7 mm malignant
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melanoma located in the conjunctiva with a minimal re-
section’s margin. The patient was re-operated one
month later and the pathology report revealed a
remnant of the melanoma with still a minimal resection’s
margin. Therefore, the patient received cryotherapy.
Four months after the first surgical procedure five new
tumor lesions were detected in the same eye. Treatment
with mitomycin eye drops was initiated, however enu-
cleation of the right eye had to be carried out two
months later to obtain local control. One month post
enucleation, a CT scan of the chest and abdomen
showed no metastases. However, yet two months later,
positron emission tomography with 2-deoxy-2-[fluor-
ine-18] fluoro-D-glucose integrated with computed
tomography (18 F-FDG PET/CT also referred as PET/
CT scan) revealed an orbital, a parotid gland and a
suspected lung metastasis. Treatment with temozolo-
mide was started and carried on for five months until
progressive disease in all locations including the lung
was noted in a new PET/CT scan. Shortly thereafter,
the patient was included in a trial and received
immunostimulatory gene therapy with the investiga-
tional drug AdCD40L in combination with low dose
cyclophosphamide. Specifically, the patient received
four weekly ultrasound-guided intratumoral injections
in the parotid gland. Three days after the final injec-
tion, a CT-brain scan was performed due to left-sided
leg weakness and revealed bleeding brain metastases.
An MRI scan confirmed the presence of five brain
metastases and the patient received whole brain
radiotherapy (4 Gy × 5). A PET/CT scan at that time
point showed progression in all lesions except the
parotid compared with the most recent PET/CT scan
(Fig. 1a).
Tissue from the primary tumor was tested for BRAF
status, revealing the presence of the V600E mutation.
One month after the whole brain radiotherapy, vemur-
afenib treatment (standard dose: 960 mg po q 12 h) was
initiated. The patient responded rapidly to the treatment;
the metastases in the parotid gland and orbit were re-
duced in size within a week. After two weeks of therapy,
the patient experienced maculopapular rash located on
the head’s uppermost part, classified as grade 2 accord-
ing to common terminology criteria for adverse events
(CTCAE version 4.0), and the treatment was paused.
One week later the rash was improved to grade 1 and
the treatment was re-started at a lower dose (25 % re-
duction of the initial dose), whereafter no side effects
were observed. After four weeks of vemurafenib treat-
ment, the above-described clinically detectable metasta-
ses in the parotid gland and orbit had disappeared. At
the next clinical examination, yet two months later, the
patient’s general condition was considerably improved
without clinical signs of disease progression. A PET/CT
scan one month later, confirmed the reduction of tumor
burden in all locations compared to the pretreatment
examination (Fig. 1b). In particular, the parotid metasta-
sis had only minor residual FDG-uptake and the size of
and the FDG-uptake in the lung metastasis had de-
creased. However, at that time the orbital lesion had
clinically reoccurred, measuring one centimeter in diam-
eter indicating progressive disease. Based on this latter
finding in combination with the worsened general condi-
tion of the patient, the treatment was assessed as no lon-
ger effective and was discontinued. The total duration of
the BRAF therapy was four months. A new CT scan of
the brain was planned in order to map the brain metas-
tases and determine the possibility to repeat radiother-
apy. However, the patient’s clinical condition quickly
deteriorated. Therefore, she underwent the CT scan
earlier than scheduled whereby more brain metastases,
than had previously been detected, were diagnosed. The
Fig. 1 a FDG-PET/CT in December 2012, prior to BRAF inhibitor therapy, showed intensely FDG avid lesions in the orbit, the parotid glad and the
lung post AdCD40L treatment. b PET/CT in May 2013, after the initiation of the treatment with vemurafenib, showed that all the previously
described intensely FDG avid lesions had lower SUVmax uptake. Physiologic FDG uptake in right posterior vocal cord is observed. Black arrow:
metastasis in right parotid gland. White arrow: metastasis in right orbit. Striped arrow: lung metastasis
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patient passed away the day after. The time schedule for
the case is depicted in Fig. 2. The pathology report was
eventually reviewed and it was ensured that the diagno-
sis indeed was CMM.
Discussion
We report on a patient with disseminated CMM who
was treated with the BRAF kinase inhibitor vemurafenib
due to the presence of the BRAFV600E mutation. She had
received all established treatments and even experimen-
tal therapy; AdCD40L.
Ocular melanoma is a rare type of malignant melan-
oma. For most small and medium size tumors, irradi-
ation is recommended. Surgery is often the treatment of
choice for recurrent disease, after initial radiotherapy.
Approximately half of the patients with ocular melan-
oma develop metastatic disease [11]. In general, progno-
sis is very poor for patients with advanced disease, and
without treatment the median survival is around eight
months [12].
In the common clinical practice, all patients with ad-
vanced cutaneous malignant melanoma who meet the
criteria for treatment with a BRAF inhibitor are tested
for the presence of the BRAF mutation [13]. However,
BRAF therapy is not established for patients with CMM
or other ocular melanomas. Vemurafenib is a highly se-
lective inhibitor of mutated BRAF, it induces objective
responses in 50 % of patients and prolongs survival
when compared to traditional chemotherapeutic agents
[14–16]. The drug is even effective in patients with brain
metastases [17]. Unfortunately, most, if not all, patients
eventually develop resistance to vemurafenib [18–20].
For many years it was thought that patients with ocular
melanoma could not benefit from treatment with BRAF-
kinase inhibitors due to the fact that the RAS-BRAF kin-
ase pathway is not involved in the most common ocular
melanoma, the choroidal melanoma [10, 21]. However, it
was eventually shown that BRAF mutations are present
in conjunctival melanomas [5, 7].
Since the patient had received and experienced disease
progression on all established treatments, vemurafenib
treatment was considered an option. A clear correlation
between the on-set of vemurafenib therapy and the re-
gression of the metastases in the orbit and parotid gland
was clinically observed. However, it cannot be ruled out
that the major regression of the metastasis of the orbit
partly was a result of the whole brain radiotherapy. It is
also unclear whether the response in the parotid gland
represents an effect of vemurafenib alone. A late syner-
gistic effect with gene therapy (AdCD40L) is possible
despite the obvious systemic resistance to that treatment
as pointed out with the occurrence of brain metastases
after the last injection of AdCD40L. Of note is that there
was a clear response in the non-localized treated lung
metastasis emphasizing that the vemurafenib treatment
was beneficial. In the only conducted study with
AdCD40L administered in metastatic melanoma patients
no late immune responses were noted [22]. In addition,
other immunotherapy approaches in ocular melanoma
patients have not proved effective in contrast to cutaneous
Fig. 2 Schematic timeline from the day the patient was diagnosed with conjunctival malignant melanoma (CMM) until she was deceased. PD:
progressive disease
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melanoma. In fact, treatment with the anti-CTLA-4
antibody ipilimumab showed limited treatment benefit
[23–25] and preliminary data from ongoing clinical
trials with PD-1 antibodies are not encouraging [26].
It is therefore unlikely that the patient’s response repre-
sents a late systemic synergistic effect with AdCD40L
treatment.
The treatment was well tolerated after an early 25 %
reduction of the initial dose. The patient’s general condi-
tion was considerably improved alongside with rapid
regression of tumor lesions. The patient passed away five
months after the initiation of the treatment with vemur-
afenib, shortly after the treatment’s discontinuation.
According to the registration trial and Drummer et al.
[14–17] the median progression free survival after
vemurafenib treatment is 3.9 months for patients with
BRAFV600E-mutant metastatic cutaneous malignant mel-
anoma with non-excisable previously treated brain me-
tastases. The patient described in this case report clearly
benefitted from the treatment and the gain was very
similar to the average for the corresponding group of pa-
tients with cutaneous malignant melanoma.
It is reasonable to believe that all patients with
BRAF-mutant cancer would benefit from treatment
with BRAF inhibitors. However, colon cancer pa-
tients harboring the BRAFV600E oncogenic lesion
have a poor prognosis and do not respond to vemur-
afenib therapy. It was shown that this unresponsive-
ness depends on BRAF inhibition through feedback
activation of EGFR [27].
Two attempts of treating metastatic CMM with
vemurafenib have previously been reported. One of these
patients experienced a mixed response, which after a
short period was followed by evident disease progression
[28]. In a Chinese CMM trial one of the patients’ tumor
was tested positive for the BRAF mutation and treat-
ment with vemurafenib was given. However, the out-
come was unclear for this second reported case [29]. In
addition, a patient who received dabrafenib experienced
an objective response but disease progression was evi-
dent after 6 months [30].
Conclusions
In conclusion, we show for the first time that treatment
of BRAF mutated metastatic CMMs with vemurafenib
could be of value. Further studies are needed to assess
the efficacy of BRAF and PD1 inhibitors in the different
subtypes of ocular melanoma.
The CMM subtype of ocular melanoma is however
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